|
Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >
Macrolide treatment for COVID-19 : Will this be the way forward?
| Title: | Macrolide treatment for COVID-19 : Will this be the way forward? |
| Authors: | Ohe, Masashi Browse this author | | Shida, Haruki Browse this author | | Jodo, Satoshi Browse this author | | Kusunoki, Yoshihiro Browse this author | | Seki, Masahide Browse this author | | Furuya, Ken Browse this author | | Goudarzi, Houman Browse this author →KAKEN DB |
| Keywords: | COVID-19 | | SARS-CoV-2 | | macrolide |
| Issue Date: | Apr-2020 |
| Publisher: | IRCA-BSSA |
| Journal Title: | BioScience Trends |
| Volume: | 14 |
| Issue: | 2 |
| Start Page: | 159 |
| End Page: | 160 |
| Publisher DOI: | 10.5582/bst.2020.03058 |
| Abstract: | The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic that has developed in late 2019 and 2020 is a serious threat to human health. With no vaccines or drugs approved for prevention and treatment until now, all efforts at drug design and/or clinical trials of already approved drugs are worthy and creditable. Using structure-based drug selection for identification of SARS-CoV-2 protease inhibitors, old drugs such as macrolides (MAC) were predicted to be effective for COVID-19. Lately, the anti-viral effects of macrolides have attracted considerable attention. Very recently, hydroxychloroquine in combination with azithromycin treatment was reported to be effective for COVID-19. We believe that treatments with macrolides alone or in combination with other drugs are promising and open the possibility of an international strategy to fight this emerging viral infection. |
| Type: | article |
| URI: | http://hdl.handle.net/2115/78986 |
| Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
|
